SOUTH
SAN FRANCISCO, Calif., March 28,
2024 /PRNewswire/ -- Calico Life Sciences LLC
(Calico), a biotechnology organization focused on the biology of
aging and age-related diseases, and founded by Alphabet and
Arthur D. Levinson, Ph.D., today
announced the appointment of Michael
Lenardo, M.D., as its new Chief Scientific Officer. Dr.
Lenardo will join the company in August after completing his term
as Co-Director of the National Institute of Allergy and Infectious
Diseases (NIAID) Clinical Genomics Program at the National
Institutes of Health.
Dr. Lenardo is an accomplished molecular immunologist and
geneticist whose medical research career spans four decades. He has
been recognized for his work on fundamental immunological
mechanisms and is particularly known for discovering the genetic
basis, pathogenesis, and treatment of several congenital disorders
of the immune system.
"Securing someone of Mike's caliber for the critical role of
Chief Scientific Officer is a major achievement for Calico," said
Dr. Levinson, CEO of Calico. "His outstanding scientific background
and collaborative nature, combined with a track record of
innovation and leadership will serve Calico well as we accelerate
into our second decade and continue to advance our mission of
understanding the biology that controls human aging and developing
interventions to allow people to lead longer and healthier
lives."
In addition to directing NIAID's Clinical Genomics Program, Dr.
Lenardo currently serves as an NIH Distinguished Investigator and
the Institute's Chief of Molecular Development of the Immune System
section. He has worked at NIAID since 1989, when he established an
independent research unit there. Dr. Lenardo has been recognized
with numerous awards and designations such as membership into the
National Academy of Sciences and the National Academy of Medicine,
and designated an Officer of the Most Excellent Order of the
British Empire (O.B.E), conferred by Queen
Elizabeth II. He received his bachelor's degree in Natural
Sciences from Johns Hopkins University
and his medical degree from Washington
University in St. Louis.
Dr. Lenardo completed his residency in internal medicine and
research in biochemistry at the University of
Iowa. He performed his postdoctoral training with Nobel
laureates David Baltimore and
Phillip Sharp at the Whitehead
Institute for Biomedical Research at the Massachusetts Institute of Technology.
"Working to answer the big scientific and medical questions
about how we age is an incredibly important mission that has the
potential to help all of us experience longer healthspans," said
Dr. Lenardo. "The commitment to scientific excellence and integrity
at Calico, coupled with the highly talented team, is truly
impressive and reflected in the impactful progress they are making.
I am looking forward to being a part of this unique and highly
collaborative organization."
About Calico
Calico (Calico Life Sciences LLC) is an
Alphabet-founded research and development company whose mission is
to harness advanced technologies and model systems to increase our
understanding of the biology that controls human aging. Calico will
use that knowledge to devise interventions that enable people to
lead longer and healthier lives. To learn more about Calico, visit
www.calicolabs.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calico-appoints-michael-lenardo-md-as-chief-scientific-officer-302101856.html
SOURCE Calico